Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Holler

Showing results (251-260 of 265) with videos related to

Pageof 27
Sort By:
Annals of Hematology|April 18, 2019
Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patientsP Lamby, D Wolff, S Mielke, et al.
Bone Marrow Transplantation|March 2, 2011
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot studyC Schmid, M Schleuning, J Tischer, et al.
Blood|December 23, 2022
Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCTF Karl, C Liang, R Böttcher-Loschinski, et al.
Bone Marrow Transplantation|January 26, 2018
Biomarkers in chronic graft-versus-host disease: quo vadis?D Wolff, H Greinix, S J Lee, et al.
Bone Marrow Transplantation|July 28, 2015
Predicting survival using clinical risk scores and non-HLA immunogeneticsY Balavarca, K Pearce, J Norden, et al.
Bone Marrow Transplantation|February 9, 2016
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomasF Heinzelmann, W Bethge, D W Beelen, et al.
Deutsche Medizinische Wochenschrift (1946)|November 9, 2001
[Epidemiology and interventional treatment strategies of infectious complications after allogenic stem-cell transplantation]H Einsele, H Bertz, J Beyer, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|July 30, 2013
Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practiceT Ruutu, A Gratwohl, T de Witte, et al.
Leukemia|July 12, 2013
Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantationE M Weissinger, J Metzger, C Dobbelstein, et al.
Pageof 27

Showing results (251-260 of 265) with videos related to

Sort By:
Pageof 27
Annals of Hematology|April 18, 2019
Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patientsP Lamby, D Wolff, S Mielke, et al.
Bone Marrow Transplantation|March 2, 2011
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot studyC Schmid, M Schleuning, J Tischer, et al.
Blood|December 23, 2022
Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCTF Karl, C Liang, R Böttcher-Loschinski, et al.
Bone Marrow Transplantation|January 26, 2018
Biomarkers in chronic graft-versus-host disease: quo vadis?D Wolff, H Greinix, S J Lee, et al.
Bone Marrow Transplantation|July 28, 2015
Predicting survival using clinical risk scores and non-HLA immunogeneticsY Balavarca, K Pearce, J Norden, et al.
Bone Marrow Transplantation|February 9, 2016
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomasF Heinzelmann, W Bethge, D W Beelen, et al.
Deutsche Medizinische Wochenschrift (1946)|November 9, 2001
[Epidemiology and interventional treatment strategies of infectious complications after allogenic stem-cell transplantation]H Einsele, H Bertz, J Beyer, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|July 30, 2013
Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practiceT Ruutu, A Gratwohl, T de Witte, et al.
Leukemia|July 12, 2013
Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantationE M Weissinger, J Metzger, C Dobbelstein, et al.
Pageof 27